Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte–colony‐stimulating factor [G‐CSF], G‐CSF plus plerixafor, or cyclophosphamide G‐CSF/granulocyte‐macrophage [GM]‐CSF) on number of colony‐forming unit–GM, engraftment, and Day +100 hematopoietic graft function

Abstract

Plerixafor-based mobilization is associated with slightly reduced number of CFU-GM and minimal delay in engraftment that is independent of CD34+ cell dose. Hematopoietic graft function on Day 100 is not affected by mobilization strategy.